Global Health Ltd (BSE: 543654, NSE: MEDANTA) — Business Report / Investor Feed

Business & Distribution Evaluation — Global Health Limited (Medanta)

1. Business Identity

Global Health Limited, operating under the "Medanta" brand, is one of the largest private multi-specialty tertiary and quaternary care hospital chains operating in the North and East regions of India, with key specialties in cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology [3][49]. The company was incorporated on August 13, 2004 under the Companies Act, 1956 (CIN: L85110DL2004PLC128319), with its registered office at E-18, Defence Colony, New Delhi [4][13].

Founder & Promoter: Dr. Naresh Trehan, Chairman and Managing Director — a world-renowned cardiovascular and cardiothoracic surgeon, recipient of the Padma Bhushan, Padma Shri, and Dr. B.C. Roy Award [47][49]. Listed on BSE (543654) and NSE (Medanta) [7].

Sector classification: Healthcare services — single business segment as identified by the CODM [31][44].

Brand recognition: Recognized as India's best private hospital by Newsweek for six consecutive years; the only Indian private hospital in the global top 150 [1][28].

2. Revenue Architecture

Revenue Model Type

Hospital-based healthcare services — revenue is generated primarily through inpatient (IPD) and outpatient (OPD) healthcare services, supplemented by in-house pharmacy sales (hospital and retail), diagnostic labs, and international medical tourism. Single operating segment: Healthcare Services [8][31].

Consolidated Financial Performance

*FY23 derived from stated 21% YoY growth to FY24. **FY25 PAT includes one-time exceptional expense of ₹499M related to MHPL merger; adjusted PAT was ₹5,186M (13.8% margin) [41].

Sources: [20][3][7][9][30][41]

Long-term growth trajectory: Total income CAGR of 22% and EBITDA CAGR of 40% from FY20 to FY24, with EBITDA margins improving from 15.1% to 26.1% over this period [2]. FY25 consolidated income grew 12.6% YoY to ₹37,714 million [40][41].

Revenue growth is decelerating from a 22% income CAGR (FY20–FY24) to 12.6% in FY25, as the base effect of mature hospitals kicks in. Future re-acceleration depends on the ~3,000-bed expansion pipeline ramping successfully — particularly Noida and Mumbai.

Revenue Mix by Hospital Category

Sources: [2][40][32]

Mature hospitals [FY25]: Revenue of ₹26,119M (+11% YoY), EBITDA of ₹6,481M (+12% YoY), EBITDA margin of 25%, occupancy at 64% [32].

Developing hospitals [FY25]: Revenue of ₹10,940M (+10% YoY), EBITDA of ₹3,290M (+2% YoY), strong EBITDA margins at 30%, but ARPOB declined 4% YoY to ₹54,303 due to increased PPP/scheme patient share [32].

Developing hospitals (Lucknow, Patna) already generate 30% EBITDA margins — higher than mature hospitals at 25% — despite being earlier in their lifecycle. This reflects the capital-light operating model in these geographies and the high operating leverage inherent in a largely fixed-cost hospital business.

Q2 FY26 update — Developing hospitals (incl. Noida): Revenue grew 30% YoY to ₹3,570M; excluding Noida, revenue grew 28% to ₹3,531M. EBITDA excl. Noida was ₹1,112M (+34% YoY) with 31.5% margin. Occupancy reached 70% (excl. Noida) [42].

Q2 FY26 update — Mature hospitals: Revenue of ₹7,200M; adjusted for OPD pharmacy business transfer to subsidiary, growth was 7.9% YoY. ARPOB reached ₹73,447 (+10% YoY driven by specialty mix) [42].

Revenue Mix by Customer Geography

Sources: [2][40][7][9]

International patient revenue is almost exclusively from Gurgaon [37]. Growth was impacted by geopolitical factors in Afghanistan, Iraq, and Bangladesh [37], but recovered to +34% YoY in Q1 FY26 and +49% YoY in Q2 FY26 [7][9].

Ancillary Revenue Streams

Sources: [2][32]. Note: From Q2 FY26, Gurgaon OPD pharmacy revenue transferred to 100% subsidiary GHL Pharma & Diagnostics Pvt Ltd; all OPD pharmacies across the network now operate under this subsidiary [46][42].

Pricing Mechanism

• Tariff-based pricing at published hospital rates; conservative approach to tariff increases [21][26].
• Patna: No tariff increase since inception (~4 years); ~75-80% of business at hospital tariffs, ~15-17% PPP volumes (against a 25% cap) at CGHS tariffs [21][38].
• Lucknow: Only nominal tariff increases taken [21].
• Gurgaon: Periodic tariff hikes considered every ~2 years, particularly for insurance contract renewals [26].
• Revenue growth has been primarily volume-led rather than price-driven, with ARPOB growth typically in the 3-7% range on an annualized basis within the Medanta ecosystem [38][29].
• CGHS rate revision [FY26]: Rates increased after several years; impact is specialty-specific — ENT saw high growth, major departments like Cardiology/Cancer saw 5-10% procedure-level increases. However, CGHS collections remain a challenge versus cash/insurance business [36].
• The business operates on a largely fixed-cost model — marginal cost to serve each incremental patient is significantly lower, providing operating leverage as volumes grow [45].

Payer Mix [FY25]

Source: [6][22][45][46]. CGHS and ECHS contribution is roughly split 50:50 within the 11-12% share [46]. For Lucknow and Patna individually, cash/TPA share is closer to 85-90% [22].

3. Product & Service Portfolio

Core Clinical Offerings

The company provides healthcare services across 30+ medical specialties [47][49], with the following key service lines:

Key Differentiators

• Proprietary clinical brand: Only Indian private hospital in Newsweek's global top 150 for six consecutive years [1][28].
• Accreditations: NABH, NABL, and JCI certifications [14].
• Technology leadership: Da Vinci Xi robotic systems, Artis Icono AI-driven BiPlane Cath Labs, 3 Tesla MRI, 256-Slice Dual Source CT, PET Scan, O-Arm imaging, patented Brachytherapy device (MAOLO) for cervical cancer treatment [1][41].
• Doctor-led model: 2,150+ doctors across the network [Sep 2025], with 100+ doctors onboarded in FY25 and 35+ senior clinicians in Q1 FY25 alone [49][41][43].
• e-ICU program: Command centres at Lucknow to extend critical care access to underserved Tier 3 and Tier 4 towns [20].
• Case mix evolution: Movement towards higher-acuity procedures — robotic surgery, TAVI, precision oncology/immunotherapy — improves realizations over time [38].

Recent Launches [FY25–H1 FY26]

• CAR-T cell therapy at Lucknow (first in the region) and Gurgaon [43][1]
• Da Vinci Xi surgical robot and third biplane cath lab commissioned at Lucknow [32][45]
• Medanta Noida commenced operations (Sep 2025) with 300 beds, 20+ super specialties, 226 beds live by Q2 FY26 [10][42]
• New 110-bed hospital in Ranchi operationalized (Jul 2025) via O&M agreement [39]
• Medanta clinics launched at Golf Course Road, Gurgaon and Ranchi city centre [32]
• 7 new retail pharmacies; Medanta Labs expanded by 2 new labs + 1 National Reference Lab [FY25] [27]
• Patent secured for MAOLO brachytherapy device; manufacturing partner being identified [41]

4. Value Chain Position

Position: Medanta operates as an integrated tertiary/quaternary care provider — combining the roles of brand owner, care provider, and distributor of healthcare services directly to end patients.

Integration direction: Primarily forward-integrated — extending from hospital-based care into diagnostics (Medanta Labs via subsidiary), retail pharmacy (GHL Pharma & Diagnostics Pvt Ltd — 100% subsidiary), e-ICU remote care, and planned service apartments [2][20][46].

Corporate structure note: All OPD/retail pharmacy operations and all retail lab operations are consolidated under the 100% subsidiary GHL Pharma & Diagnostics Pvt Ltd. Hospital labs remain within the hospital entities [46]. MHPL (Lucknow unit) was amalgamated with GHL effective April 1, 2024 (NCLT order Feb 2025), enabling EPCG export benefits, optimized cash flow utilization, and reduced compliance complexity [35][44].

Key Inputs & Cost Structure [FY25 (S)]

Source: [13]. Standalone figures (S); post-amalgamation with MHPL.

Source: [30]

Employee costs + retainer/consultant fees together constitute ~44% of total expenses, underscoring the specialist-driven nature of the business. With employee cost growth (20.5% YoY in Q1 FY26) outpacing revenue growth — driven by Noida/Ranchi hiring and ESOP expenses — margin expansion will depend on volume throughput catching up to the expanded cost base.

Key observations:

• Employee costs + retainer/consultant fees together constitute ~44% of total expenses, reflecting the doctor-heavy, specialist-driven nature of the business [13].
• Employee cost growth (20.5% YoY in Q1 FY26) outpaced revenue growth, driven by annual increments, new hiring for Noida/Ranchi expansion, and ESOP expenses (₹79M in Q1 FY26) [30][33].
• Finance costs declined from ₹424M to ₹334M (FY24→FY25), reflecting deleveraging; net cash surplus of ₹8,123 million as at Mar 31, 2025 [5][39].
• Capex of ₹6,449M in FY25, of which ₹1,367M was towards Mumbai hospital [39].

5. Distribution Architecture

Channel Structure

Medanta operates a direct-to-patient model — patients access care directly through hospital OPD/IPD, emergency services, Medanta clinics, and the Medanta Labs collection centre network. There is no intermediary-based distribution.

Network Scale

Hospital footprint evolution:

Sources: [34][30][47][49]

Hospital-wise bed capacity:

Sources: [12][17][10][42][33]

Note on Ranchi reclassification: While Ranchi is classified as a "mature" hospital, the new 110-bed expansion unit within it carries developing-stage economics, including additional manpower and launch costs [33].

Operational Metrics — Healthcare Sector-Specific

Sources: [34][30][7][9] *Sep 30, 2025 per [49]

Management frames occupancy at ~62% as misleading in isolation — with an ALOS of ~3 days (described as "amongst the best in the industry"), even a 0.5–1 day increase would push occupancy to 70-75%, which is functional capacity for a complex-care system. The right metric to track is IP volume throughput (+11.7% YoY in FY25), not headline occupancy.

Occupancy ceiling context: Management notes that with ALOS of ~3 days, if ALOS increased by just 0.5–1 day, occupancy would reach 70-75%. For a complex-care system like Medanta, 70-75% midnight occupancy is functionally near capacity; above that, the system "starts to get choked." The right metric is throughput (IP volume growth), not standalone occupancy [37].

Expansion Pipeline (~3,000 additional beds over 3-4 years)

Total planned capex: ~₹4,000 crores over next 3-4 years for ~3,000 bed addition, plus ~₹450 crores maintenance capex. Investment expected to be back-ended, funded through internal accruals and debt financing [35].

Bed addition timeline: ~1,000 beds in the next 2 years (from May 2025); another ~2,000 beds across greenfield projects over the subsequent 3-4 years [39].

The expansion strategy is notably capital-efficient — of the ~3,000 planned beds, a significant portion (Pitampura ~780, Ranchi 110, South Delhi ~400) uses asset-light models (O&M agreements, JVs) where third parties bear civil infrastructure costs. Combined with a ₹8,123M net cash surplus, Medanta can fund growth without material leverage, preserving balance sheet optionality.

Ancillary Distribution Networks [Q1 FY26]

All retail lab and OPD pharmacy operations are consolidated under GHL Pharma & Diagnostics Pvt Ltd (100% subsidiary). Hospital labs remain within hospital entities [46].

Distribution Moat

• Clinical brand: Six-year running Newsweek #1 Indian private hospital ranking; significant time to replicate reputation and doctor network [1].
• No competitive attrition observed: Management states no significant clinical attrition, no patient volume dip, and no feedback of patients preferring competitors — "everything firing on all cylinders" for the last 3-4+ quarters [36].
• Doctor ecosystem: 2,150+ doctors [Sep 2025], with active onboarding of 100+ doctors annually and 7 new directors + 20+ senior clinicians added to Lucknow alone in FY25 [49][32].
• Geographic first-mover: Largest private hospital beds under one roof in Delhi NCR, Uttar Pradesh, and Bihar [12][17]. Long-term commitment to UP region with a large-format institutional approach rather than small facilities [45].
• Breakeven speed: Both Patna and Lucknow achieved EBITDA breakeven within the first year of operations [18].
• Asset-light expansion models: O&M agreement (Pitampura — 30-year term, Society builds civil infra, Medanta invests in fitouts/equipment and operates; service fees as % of net revenue or minimum commitment) [48], JV (South Delhi with DLF), and lease (Ranchi new unit) enable capital-efficient geographic expansion [23][11].
• Insurance empanelment relationships: Active and established relationships with all major insurance providers; working to fast-track empanelment for new Noida facility [36].

6. Customer Profile

Customer Segments

Customer Concentration

No single-customer concentration risk — being a hospital chain, revenue is derived from a highly fragmented base of individual patients. The business operates on a spot/episodic basis (patient-by-patient) [2].

Relationship Depth

• Contract type: Predominantly spot/episodic, with recurring insurance/TPA contracts renewed periodically (~every 2 years for tariff negotiations) [26].
• PPP arrangement (Patna): Current PPP volumes at 15-17% of total Patna volumes, against a cap of 25%. Management is actively working with the government to increase this share, citing good realizations and favorable payment terms [38].
• Scheme empanelment: Enrolled in Ayushman Bharat, CGHS, ECHS across all hospitals including recent enrollment at Lucknow [45][32].
• Switching costs: High for complex tertiary/quaternary care due to established doctor-patient relationships, institutional reputation, and specialized equipment. Management notes continued commitment to serve all segments — "our right, our duty to serve every segment of society" [45].
• CGHS collections challenge: While CGHS rate increases are positive, collections and payment timelines remain a challenge versus cash/insurance business [36].

Acquisition Model

• Referral & reputation-driven: Doctor-led model; clinical brand drives patient acquisition [25].
• Volume-led growth strategy: Consistent double-digit IP and OP volume growth across both mature and developing hospitals [32][41].
• Scheme empanelment: Government schemes serve as a volume driver, particularly at developing hospitals, even though they are marginally ARPOB-dilutive [32].
• International medical tourism: Dedicated channel; recovering from geopolitical disruptions (Afghanistan, Iraq, Bangladesh) with strong Q1-Q2 FY26 rebound [37].
• Digital/remote: e-ICU programme bridges access to Tier 3/4 towns and acts as a patient funnel [20].
• Ancillary touchpoints: Medanta Labs collection centres (~300), retail pharmacies, and Medanta clinics create additional patient access points and acquisition channels [19][32].

Healthcare Sector-Specific Metrics Summary

Competitive Distribution Comparison

Data gap: Competitor-specific distribution data (peer hospital chains such as Apollo, Max Healthcare, Fortis, Narayana Health) is not available in the provided filings. A side-by-side comparison cannot be produced from the evidence base.

Qualitative positioning based on management commentary:

• Medanta faces increased competitive intensity in Lucknow and across India, with competitors following Medanta into Tier-2 markets — but management has seen no significant impact on patient volumes or clinical attrition [36][24].
• The company's large-format, single-roof hospital model (1,440 beds in Gurgaon, 757 in Lucknow) differs from competitors' more distributed, smaller-unit models [15][45].
• Mumbai expansion at ~₹2 Cr/bed (including land) is positioned as competitive versus industry benchmarks [15].
• Volume-led growth (rather than tariff-driven) in mature facilities is noted as a differentiator versus peers who rely more on price increases [29].
• ALOS of ~3 days is described as "amongst the best in the industry" [37].

Key Data Gaps

1. Revenue mix by specialty/therapy area — referenced in presentations as images but not extractable as text [5].
2. IPD/OPD split of revenue — not explicitly quantified as a percentage.
3. Competitor benchmarking data — absent from filings; no peer comparison possible.
4. Digital distribution/online revenue share — not disclosed beyond the e-ICU programme.
5. Detailed geographic revenue split beyond mature/developing — unit-level revenue for individual hospitals not separately disclosed (except Q2 FY26 where developing excl./incl. Noida is broken out [42]).
6. Supplier concentration — not explicitly disclosed, though diversified sourcing across multiple equipment OEMs (Siemens, Intuitive Surgical, Varian) and pharmaceutical suppliers is implied.
7. Channel economics for Medanta Labs/Pharmacy — margin profiles, credit terms for collection centres and retail pharmacies not disclosed separately.